LG007 as a potential treatment for triple-negative breast cancer
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
Researchers are developing LG007, a new drug aimed at treating people with triple-negative breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11188985 on NIH RePORTER |
What this research studies
This project tests LG007 using human tumor tissue grown in mice (patient-derived xenograft models) to see whether the drug can shrink tumors and prevent spread. Early lab and animal results showed LG007 can dramatically reduce tumor size and limit metastasis in these models. The team will run more preclinical experiments to confirm activity and safety before any human testing. If those results hold up, the work is intended to support moving LG007 toward clinical trials in people with TNBC.
Who could benefit from this research
Good fit: People with triple-negative breast cancer—especially those with advanced, recurrent, or metastatic disease who have limited treatment options—would be the likely candidates for future clinical testing.
Not a fit: People with non–triple-negative breast cancer subtypes or anyone seeking immediate, approved treatments should not expect direct benefit from this preclinical research.
Why it matters
Potential benefit: If successful, LG007 could become a new option that reduces tumor growth and metastasis in people with triple-negative breast cancer.
How similar studies have performed: Some targeted and immune-based treatments help certain subgroups of TNBC patients, but LG007 is a novel agent with promising preclinical effects and has not yet been tested in people.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Xi, Yaguang — University of Georgia
- Study coordinator: Xi, Yaguang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.